Výsledky vyhledávání - "Kumar Kandadi Muralidharan"

Akademický článek

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid

Autor: Lin Lin, Fei Hua, Cristian Salinas, Carissa Young, Thierry Bussiere, Joshua F. Apgar, John M. Burke, Kumar Kandadi Muralidharan, Rajasimhan Rajagovindan, Ivan Nestorov

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 3, Pp 362-372 (2022)

Abstract Alzheimer's disease (AD) is an irreversible, progressive brain disorder that impairs memory and cognitive function. Dysregulation of the amyloid‐β (Aβ) pathway and amyloid plaque accumulation in the brain are hallmarks of AD. Aducanumab

Externí odkaz: https://doaj.org/article/7f7bb9c94560451a90a1143017ac5a1c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

Autor: Kumar Kandadi Muralidharan, Xiao Tong, Kenneth G. Kowalski, Raj Rajagovindan, Lin Lin, Samantha Budd Haberlain, Ivan Nestorov

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 7-19 (2022)

Abstract Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease. This paper describes the relationship between the population pharmacok

Externí odkaz: https://doaj.org/article/6a0a7cf76a734c6fab8a7a9f6a676938

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

Autor: Mita Kuchimanchi, Michael Monine, Kumar Kandadi Muralidharan, Caroline Woodward, Natalia Penner

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 515-522 (2020)

This modeling and simulation analysis was aimed at selecting doses of cinpanemab (BIIB054), a monoclonal antibody targeting aggregated α‐synuclein, for a phase II study in Parkinson’s disease (PD). Doses and regimens were proposed based on antic

Externí odkaz: https://doaj.org/article/dbffe77d3e484d199ea8344fe935395f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials

Autor: Kumar Kandadi Muralidharan, Kenneth G. Kowalski, Xiao Tong, Samantha Budd Haeberlein, Rajasimhan Rajagovindan, Ivan Nestorov

Publikováno v: Journal of Pharmacokinetics and Pharmacodynamics. 50:45-62

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca54b16e0d9ecd18d92b8dbb2747d2c5
https://doi.org/10.1007/s10928-022-09839-3

Zobrazit plný text záznamu

Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials

Autor: Kumar Kandadi Muralidharan, Kenneth G. Kowalski, Xiao Tong, Samantha Budd Haeberlein, Rajasimhan Rajagovindan, Ivan Nestoro

Publikováno v: Journal of Pharmacokinetics and Pharmacodynamics.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65aef2f96f1a70b3ccb2697da61a2c85
https://doi.org/10.1007/s10928-023-09852-0

Zobrazit plný text záznamu

A Time‐to‐Event Exposure‐Response Model for Amyloid‐Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease

Autor: Kumar Kandadi, Muralidharan, Sravan, Karumanchi, Kenneth G, Kowalski, Patrick, Burkett, Sunny, Chapel, Raj, Rajagovindan, Ivan, Nestorov

Publikováno v: The Journal of Clinical Pharmacology. 62:1030-1046

Amyloid-related imaging abnormalities with edema (ARIA-E) have been reported in patients with early Alzheimer disease treated with aducanumab. ARIA-E incidence has been observed to be dependent on both dose and apolipoprotein E4 carrier status. A tim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d43193caed65559b3188037b55b328c
https://doi.org/10.1002/jcph.2047

Zobrazit plný text záznamu

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

Autor: Xiao Tong, Kenneth G. Kowalski, Lin Lin, Raj Rajagovindan, Ivan Nestorov, Samantha Budd Haberlain, Kumar Kandadi Muralidharan

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 7-19 (2022)

Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease. This paper describes the relationship between the population pharmacokinetics (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9edab26cdb80bda2bfc2858974ed1ae
https://doi.org/10.1002/psp4.12728

Zobrazit plný text záznamu

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

Autor: Pei-Ran Ho, Ih Chang, Kumar Kandadi Muralidharan, Nolan Campbell

Publikováno v: Journal of Clinical Pharmacology

Natalizumab is approved for multiple sclerosis treatment at a dose of 300 mg every 4 weeks. Extended‐interval dosing of natalizumab has been proposed as a strategy to mitigate the risk of progressive multifocal leukoencephalopathy, but the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a6774fe173e7172ef373c4176e5345
http://europepmc.org/articles/PMC7891569

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání